Literature DB >> 21738081

PharmGKB summary: carbamazepine pathway.

Caroline F Thorn1, Susan G Leckband, John Kelsoe, J Steven Leeder, Daniel J Müller, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21738081      PMCID： PMC3349991          DOI： 10.1097/FPC.0b013e328348c6f2

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  60 in total

1.  Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.

Authors:  K Maekawa; T Yoshimura; Y Saito; Y Fujimura; F Aohara; C Emoto; K Iwasaki; N Hanioka; S Narimatsu; T Niwa; J Sawada
Journal:  Xenobiotica       Date:  2009-02       Impact factor: 1.908

2.  Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression.

Authors:  Patrick Kwan; Wai Sang Poon; Ho-Keung Ng; David E Kang; Virginia Wong; Ping Wing Ng; Colin H T Lui; Ngai Chuen Sin; Ka S Wong; Larry Baum
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

Review 3.  Clinically significant carbamazepine drug interactions: an overview.

Authors:  C E Pippenger
Journal:  Epilepsia       Date:  1987       Impact factor: 5.864

4.  Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis.

Authors:  Facundo Garcia Bournissen; Myla E Moretti; David N Juurlink; Gideon Koren; Mugabe Walker; Yaron Finkelstein
Journal:  Epilepsia       Date:  2008-10-24       Impact factor: 5.864

Review 5.  Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity.

Authors:  J L Guéant; R M Guéant-Rodriguez; I Aimone Gastin; J A Cornejo-García; M Viola; A Barbaud; P M Mertes; M Blanca; A Romano
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

6.  Several major antiepileptic drugs are substrates for human P-glycoprotein.

Authors:  Carlos Luna-Tortós; Maren Fedrowitz; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

7.  Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

Authors:  Chaichon Locharernkul; Jakrin Loplumlert; Chusak Limotai; Wiwat Korkij; Tayard Desudchit; Siraprapa Tongkobpetch; Oratai Kangwanshiratada; Nattiya Hirankarn; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Epilepsia       Date:  2008-07-14       Impact factor: 5.864

8.  Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin.

Authors:  Wei Lu; Jack P Uetrecht
Journal:  Drug Metab Dispos       Date:  2008-05-07       Impact factor: 3.922

9.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Nahoko Kaniwa; Yoshiro Saito; Michiko Aihara; Kayoko Matsunaga; Masahiro Tohkin; Kouichi Kurose; Jun-ichi Sawada; Hirokazu Furuya; Yukitoshi Takahashi; Masaaki Muramatsu; Shigeru Kinoshita; Masamichi Abe; Hiroko Ikeda; Mariko Kashiwagi; Yixuan Song; Mayumi Ueta; Chie Sotozono; Zenro Ikezawa; Ryuichi Hasegawa
Journal:  Pharmacogenomics       Date:  2008-11       Impact factor: 2.533

10.  Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.

Authors:  Mike Ufer; Igor Mosyagin; Hiltrud Muhle; Thies Jacobsen; Sierk Haenisch; Robert Häsler; Frank Faltraco; Cornelia Remmler; Sarah von Spiczak; Heyo K Kroemer; Uwe Runge; Rainer Boor; Ulrich Stephani; Ingolf Cascorbi
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089
View more
  18 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

2.  Genotypes at rs2844682 and rs3909184 have no clinical value in identifying HLA-B*15:02 carriers.

Authors:  Guang-Dan Zhu; Ashley A Brenton; Alka Malhotra; Bae J Riley; Katherine E Church; Frank G Espin; Tanya A Moreno; Jennifer M Strickland; Andria L Del Tredici
Journal:  Eur J Clin Pharmacol       Date:  2015-06-04       Impact factor: 2.953

Review 3.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

4.  Drugs of environmental concern modify Solea senegalensis physiology and biochemistry in a temperature-dependent manner.

Authors:  A González-Mira; I Varó; M Solé; A Torreblanca
Journal:  Environ Sci Pollut Res Int       Date:  2016-08-03       Impact factor: 4.223

5.  Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy.

Authors:  Sharmila Das; Dong Guo; Xiaohui Jiang; Wenlei Jiang; Yan Shu; Tricia Y Ting; James E Polli
Journal:  Pharm Res       Date:  2020-02-26       Impact factor: 4.200

Review 6.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

7.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.

Authors:  Natasa Djordjevic; Dragana Dragas Milovanovic; Marija Radovanovic; Ivan Radosavljevic; Slobodan Obradovic; Mihajlo Jakovljevic; Dragan Milovanovic; Jasmina R Milovanovic; Slobodan Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

8.  MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes.

Authors:  Yaqiong Jin; Dianke Yu; William H Tolleson; Bridgett Knox; Yong Wang; Si Chen; Zhen Ren; Helen Deng; Yongli Guo; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2016-06-14       Impact factor: 5.858

9.  Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Authors:  Elizabeth J Phillips; Chonlaphat Sukasem; Michelle Whirl-Carrillo; Daniel J Müller; Henry M Dunnenberger; Wasun Chantratita; Barry Goldspiel; Yuan-Tsong Chen; Bruce C Carleton; Alfred L George; Taisei Mushiroda; Teri Klein; Roseann S Gammal; Munir Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875

10.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.